Dexmedetomidine in Splanchnic Nerve Neurolysis

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

July 30, 2022

Conditions
Dexmedetomidine
Interventions
DRUG

Group 1

Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side

DRUG

Group 2

Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.

Trial Locations (1)

61519

Minya University, Minya

All Listed Sponsors
lead

Minia University

OTHER

NCT05291364 - Dexmedetomidine in Splanchnic Nerve Neurolysis | Biotech Hunter | Biotech Hunter